James E. Flynn

Insider Reports History

Entity
Individual
Location
780 Third Avenue, 37 Th Floor, New York, NY
Signature
/s/ Jonathan Isler, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by James E. Flynn:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Nuvalent, Inc. Director, * Director by deputization, 10%+ Owner Class A Common Stock 8.67M $848M $97.75 Oct 22, 2024 Through Deerfield Healthcare Innovations Fund, L.P.
Nuvalent, Inc. Director, * Director by deputization, 10%+ Owner Class A Common Stock 8.67M $848M $97.75 Oct 22, 2024 Through Deerfield Private Design Fund IV, L.P.
AdaptHealth Corp. *Possible Member of 10% Group, 10%+ Owner Class A Common Stock 11.5M $123M $10.70 Mar 12, 2024 Through Deerfield Partners, L.P.
Nuvalent, Inc. Director, * Director by deputization, 10%+ Owner Class A Common Stock 650K $63.5M $97.75 Oct 22, 2024 Through Deerfield Partners, L.P.
CareMax, Inc. Director, Director by Deputization, 10%+ Owner Class A Common Stock 15.8M $54.7M $3.46 Nov 17, 2023 Through Deerfield Partners, L.P.
Larimar Therapeutics, Inc. Director, * Director by Deputization, 10%+ Owner Common Stock 6.15M $53.8M $8.74 Feb 16, 2024 Through Deerfield Private Design Fund IV, L.P.
Larimar Therapeutics, Inc. Director, * Director by Deputization, 10%+ Owner Common Stock 6.15M $53.8M $8.74 Feb 16, 2024 Through Deerfield Private Design Fund III, L.P.
Mirum Pharmaceuticals, Inc. * Possible Member of 10% Group, 10%+ Owner Common Stock 1.7M $47.8M $28.04 Jun 6, 2022 Through Deerfield Private Design Fund IV, L.P.
Mirum Pharmaceuticals, Inc. * Possible Member of 10% Group, 10%+ Owner Common Stock 1.54M $43.2M $28.04 Jun 6, 2022 Through Deerfield Healthcare Innovations Fund, L.P.
Larimar Therapeutics, Inc. Director, * Director by Deputization, 10%+ Owner Common Stock 4.72M $41.3M $8.74 Feb 16, 2024 Through Deerfield Healthcare Innovations Fund, L.P.
Larimar Therapeutics, Inc. Director, * Director by Deputization, 10%+ Owner Common Stock 4.21M $36.8M $8.74 Feb 16, 2024 Through Deerfield Partners, L.P.
ARS Pharmaceuticals, Inc. Director, Director by deputization, 10%+ Owner Common Stock 5.54M $21M $3.78 Nov 8, 2022 Through Deerfield Private Design Fund III, L.P.
ARS Pharmaceuticals, Inc. Director, Director by deputization, 10%+ Owner Common stock 5.54M $21M $3.78 Nov 8, 2022 Through Deerfield Private Design Fund IV, L.P.
AdaptHealth Corp. *Possible Member of 10% Group, 10%+ Owner Class A Common Stock 1.71M $18.3M $10.70 Mar 8, 2024 Through Deerfield Private Design Fund IV, L.P.
BiomX Inc. Director, *Director by Deputization Common Stock 8.94M $3.41M $0.38 Jul 15, 2024 Through Deerfield Healthcare Innovations Fund II, L.P.
BiomX Inc. Director, *Director by Deputization Common Stock 8.94M $3.41M $0.38 Jul 15, 2024 Through Deerfield Private Design Fund V, L.P.
Singular Genomics Systems, Inc. *Possible Member of 10% Group, 10%+ Owner Common Stock 7.48M $3.17M $0.42 Jun 1, 2021 Through Deerfield Private Design Fund IV, L.P.
Acutus Medical, Inc. Director, Director by Deputization, 10%+ Owner Common Stock 1.62M $2.53M $1.56 Jun 16, 2022 Through Deerfield Private Design Fund III, L.P.
Fractyl Health, Inc. Possible Members of 10% Group, 10%+ Owner Common Stock 834K $2.42M $2.90 Feb 6, 2024 Through Deerfield Private Design Fund III, L.P.
PepGen Inc. Possible Member of 10% Group, 10%+ Owner Common Stock 477K $1.99M $4.17 May 10, 2022 Through Deerfield Partners, L.P.
PepGen Inc. Possible Member of 10% Group, 10%+ Owner Common Stock 477K $1.99M $4.17 May 10, 2022 Through Deerfield Private Design Fund V, L.P.
Acutus Medical, Inc. Director, Director by Deputization, 10%+ Owner Common Stock 1.03M $1.6M $1.56 Jun 16, 2022 Through Deerfield Partners, L.P.
Xilio Therapeutics, Inc. Possible Member of 10% Group, 10%+ Owner Common Stock 1.14M $949K $0.83 Oct 26, 2021 Through Deerfield Partners, L.P.
Xilio Therapeutics, Inc. Possible Member of 10% Group, 10%+ Owner Common Stock 1.14M $949K $0.83 Oct 26, 2021 Through Deerfield Private Design Fund V, L.P.
Singular Genomics Systems, Inc. *Possible Member of 10% Group, 10%+ Owner Common Stock 1.63M $689K $0.42 Jun 1, 2021 Through Deerfield Partners, L.P.
AdaptHealth Corp. *Possible Member of 10% Group, 10%+ Owner Class A Common Stock 20K $214K $10.70 Mar 8, 2024 Through Deerfield Management Company, L.P.
CareMax, Inc. Director, Director by Deputization, 10%+ Owner Class A Common Stock 12.1K $41.9K $3.46 Nov 17, 2023 Through Deerfield Management Company, L.P.
Acutus Medical, Inc. Director, Director by Deputization, 10%+ Owner Common Stock 20.8K $32.5K $1.56 Jun 15, 2023 Through Deerfield Management Company, L.P.
BiomX Inc. Director, *Director by Deputization Warrants 20.2M Jul 9, 2024 Through Deerfield Healthcare Innovations Fund II, L.P.
BiomX Inc. Director, *Director by Deputization Warrants 20.2M Jul 9, 2024 Through Deerfield Private Design Fund V, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Private Placement Warrants 3.18M Nov 12, 2021 Through DFP Sponsor, LLC
Frazier Lifesciences Acquisition Corp Possible Member of 10% Group, 10%+ Owner Class A Ordinary Shares 2.48M Nov 8, 2022 Through Deerfield Partners, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Class A Common Stock 1.61M Nov 12, 2021 Through Deerfield Partners, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Class A Common Stock 1.61M Nov 12, 2021 Through Deerfield Private Design Fund IV, L.P.
Oncorus, Inc. Possible Member of 10% Group, 10%+ Owner Common Stock 1.16M Dec 30, 2022 Through Deerfield Healthcare Innovations Fund, L.P.
Oncorus, Inc. Possible Member of 10% Group, 10%+ Owner Common Stock 1.16M Dec 30, 2022 Through Deerfield Private Design Fund III, L.P.
Bicara Therapeutics Inc. Possible Members of 10% Group, 10%+ Owner Common Stock 898K Sep 17, 2024 Through Deerfield Partners, L.P.
Bicara Therapeutics Inc. Possible Members of 10% Group, 10%+ Owner Common Stock 898K Sep 17, 2024 Through Deerfield Private Design Fund V, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Public Warrants 625K Nov 12, 2021 Through Deerfield Partners, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Public Warrants 625K Nov 12, 2021 Through Deerfield Private Design Fund IV, L.P.
Oncorus, Inc. Possible Member of 10% Group, 10%+ Owner Common Stock 285K Dec 30, 2022 Through Deerfield Partners, L.P.
BiomX Inc. Director, *Director by Deputization Stock Option (Right to Buy) 264K Jul 11, 2024 Through Deerfield Management Company, L.P.
Acutus Medical, Inc. Director, Director by Deputization, 10%+ Owner Warrant to Purchase Common Stock 193K Jun 16, 2022 Through Deerfield Private Design Fund III, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Class A Common Stock 85.1K Nov 12, 2021 Through Deerfield Management Company, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Series A Common Stock Equivalent Convertible Preferred Stock 58.9K Nov 12, 2021 Through Deerfield Partners, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Series A Common Stock Equivalent Convertible Preferred Stock 58.9K Nov 12, 2021 Through Deerfield Private Design Fund IV, L.P.
BiomX Inc. Director, *Director by Deputization Series X Non-Voting Convertible Preferred Stock 48K Jul 15, 2024 Through Deerfield Healthcare Innovations Fund II, L.P.
BiomX Inc. Director, *Director by Deputization Series X Non-Voting Convertible Preferred Stock 48K Jul 15, 2024 Through Deerfield Private Design Fund V, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Series A Common Stock Equivalent Convertible Preferred Stock 45.6K Nov 12, 2021 Through DFP Sponsor, LLC
Acutus Medical, Inc. Director, Director by Deputization, 10%+ Owner Warrant to Purchase Common Stock 31.1K Jun 16, 2022 Through Deerfield Partners, L.P.
Singular Genomics Systems, Inc. *Possible Member of 10% Group, 10%+ Owner Stock Option (Right to Buy) 30K Jun 1, 2021 Through Deerfield Management Company, L.P.
Acutus Medical, Inc. Director, Director by Deputization, 10%+ Owner Stock Option (Right to Buy) 19.6K Jun 15, 2023 Through Deerfield Management Company, L.P.
Larimar Therapeutics, Inc. Director, * Director by Deputization, 10%+ Owner Stock Option (Right to Buy) 19K May 29, 2024 Through Deerfield Management Company, L.P.
Nuvalent, Inc. Director, * Director by deputization, 10%+ Owner Stock Option (Right to Buy) 3.79K Jun 12, 2024 Through Deerfield Management Company, L.P.
Acutus Medical, Inc. Director, Director by Deputization, 10%+ Owner Series A Common Stock Equivalent Convertible Preferred Stock 1.82K Jun 16, 2022 Through Deerfield Private Design Fund III, L.P.
Acutus Medical, Inc. Director, Director by Deputization, 10%+ Owner Series A Common Stock Equivalent Convertible Preferred Stock 948 Jun 16, 2022 Through Deerfield Partners, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Class A Common Stock 40 Nov 12, 2021 Through DFP Sponsor, LLC
Bicara Therapeutics Inc. Possible Members of 10% Group, 10%+ Owner Series C Preferred Stock 0 Sep 17, 2024 Through Deerfield Partners, L.P.
Bicara Therapeutics Inc. Possible Members of 10% Group, 10%+ Owner Series C Preferred Stock 0 Sep 17, 2024 Through Deerfield Private Design Fund V, L.P.
CareMax, Inc. Director, Director by Deputization, 10%+ Owner Restricted Stock Units 0 $3.46 Nov 17, 2023 Through Deerfield Management Company, L.P.
Fractyl Health, Inc. Possible Members of 10% Group, 10%+ Owner Series C-2 Preferred Stock 0 Feb 6, 2024 Through Deerfield Private Design Fund III, L.P.
Fractyl Health, Inc. Possible Members of 10% Group, 10%+ Owner Series D Preferred Stock 0 Feb 6, 2024 Through Deerfield Private Design Fund III, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Class B Common Stock 0 Nov 12, 2021 Through Deerfield Management Company, L.P.
Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner Class B Common Stock 0 Nov 12, 2021 Through DFP Sponsor, LLC
PepGen Inc. Possible Member of 10% Group, 10%+ Owner Series B Preferred Stock 0 May 10, 2022 Through Deerfield Partners, L.P.
PepGen Inc. Possible Member of 10% Group, 10%+ Owner Series B Preferred Stock 0 May 10, 2022 Through Deerfield Private Design Fund V, L.P.
Singular Genomics Systems, Inc. *Possible Member of 10% Group, 10%+ Owner 6% Convertible Note due 2023 0 Jun 1, 2021 Through Deerfield Partners, L.P.
Singular Genomics Systems, Inc. *Possible Member of 10% Group, 10%+ Owner 6% Convertible Note due 2023 0 Jun 1, 2021 Through Deerfield Private Design Fund IV, L.P.
Singular Genomics Systems, Inc. *Possible Member of 10% Group, 10%+ Owner Series B Preferred Stock 0 Jun 1, 2021 Through Deerfield Private Design Fund IV, L.P.
Xilio Therapeutics, Inc. Possible Member of 10% Group, 10%+ Owner Series C Preferred Stock 0 Oct 26, 2021 Through Deerfield Partners, L.P.
Xilio Therapeutics, Inc. Possible Member of 10% Group, 10%+ Owner Series C Preferred Stock 0 Oct 26, 2021 Through Deerfield Private Design Fund V, L.P.

Insider Reports Filed by James E. Flynn

Symbol Company Period Transactions Value $ Form Type Date Filed Role
NUVL Nuvalent, Inc. Oct 22, 2024 2 -$196M 4 Oct 24, 2024 Director, * Director by deputization, 10%+ Owner
BCAX Bicara Therapeutics Inc. Sep 17, 2024 6 $1.26M 4 Sep 17, 2024 Possible Members of 10% Group, 10%+ Owner
BCAX Bicara Therapeutics Inc. Sep 12, 2024 0 $0 3 Sep 12, 2024 *Possible Member of 10% Group, 10%+ Owner
PHGE BiomX Inc. Jul 15, 2024 4 $0 4 Jul 17, 2024 Director, *Director by Deputization
PHGE BiomX Inc. Jul 11, 2024 1 $0 4 Jul 15, 2024 Director, *Director by Deputization
PHGE BiomX Inc. Jul 9, 2024 4 $0 4 Jul 11, 2024 Director, *Director by Deputization, 10%+ Owner
NUVL Nuvalent, Inc. Jun 12, 2024 4 $0 4 Jun 14, 2024 Director, Director by Deputization, 10%+ Owner
LRMR Larimar Therapeutics, Inc. May 29, 2024 1 $0 4 Jun 3, 2024 Director, * Director by Deputization, 10%+ Owner
PHGE BiomX Inc. Mar 15, 2024 6 $0 4 Mar 19, 2024 Director, *Director by Deputization, 10%+ Owner
PHGE BiomX Inc. Mar 15, 2024 0 $0 3 Mar 19, 2024 Director, *Director by Deputization
AHCO AdaptHealth Corp. Mar 8, 2024 5 -$3.82M 4 Mar 12, 2024 *Possible Member of 10% Group, 10%+ Owner
AHCO AdaptHealth Corp. Feb 27, 2024 0 $0 3 Mar 8, 2024 *Possible Member of 10% Group, 10%+ Owner
LRMR Larimar Therapeutics, Inc. Feb 16, 2024 3 $37.5M 4 Feb 16, 2024 Director, * Director by Deputization, 10%+ Owner
GUTS Fractyl Health, Inc. Feb 6, 2024 4 $0 4 Feb 8, 2024 Possible Members of 10% Group, 10%+ Owner
GUTS Fractyl Health, Inc. Feb 1, 2024 0 $0 3 Feb 1, 2024 Possible Member of 10% Group, 10%+ Owner
CMAX CareMax, Inc. Nov 17, 2023 2 $0 4 Nov 21, 2023 Director, Director by Deputization, 10%+ Owner
NUVL Nuvalent, Inc. Jun 15, 2023 2 $0 4 Jun 16, 2023 Director, Director by deputization, 10%+ Owner
CMAX CareMax, Inc. Jun 8, 2023 1 $0 4 Jun 12, 2023 Director, Director by Deputization, 10%+ Owner
LRMR Larimar Therapeutics, Inc. May 9, 2023 1 $0 4 May 11, 2023 Director, * Director by Deputization, 10%+ Owner
ONCR Oncorus, Inc. Dec 28, 2022 9 -$88.3K 4 Dec 30, 2022 Possible Member of 10% Group, 10%+ Owner
ONCR Oncorus, Inc. Dec 22, 2022 6 -$19.9K 4 Dec 27, 2022 Possible Member of 10% Group, 10%+ Owner
ONCR Oncorus, Inc. Dec 19, 2022 9 -$37.6K 4 Dec 21, 2022 *Possible Member of 10% Group, 10%+ Owner
ONCR Oncorus, Inc. Dec 13, 2022 9 -$5.33K 4 Dec 15, 2022 *Possible Member of 10% Group, 10%+ Owner
CMAX CareMax, Inc. Nov 17, 2022 1 $0 4 Nov 21, 2022 Director, Director by Deputization, 10%+ Owner
FLAC Frazier Lifesciences Acquisition Corp Nov 8, 2022 0 $0 3 Nov 14, 2022 Possible Member of 10% Group, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Nov 8, 2022 0 $0 3 Nov 10, 2022 Director, Director by deputization, 10%+ Owner
NUVL Nuvalent, Inc. Nov 3, 2022 1 $21.8M 4 Nov 7, 2022 Director, Director by deputization, 10%+ Owner
LRMR Larimar Therapeutics, Inc. Sep 16, 2022 4 $35M 4 Sep 20, 2022 Director, * Director by Deputization, 10%+ Owner
AFIB Acutus Medical, Inc. Jun 30, 2022 2 $0 4 Jul 5, 2022 Director, Director by Deputization, 10%+ Owner
AFIB Acutus Medical, Inc. Jun 16, 2022 4 $0 4 Jun 20, 2023 Director, Director by deputization
NUVL Nuvalent, Inc. Jun 16, 2022 2 $0 4 Jun 21, 2022 Director, Director by Deputization, 10%+ Owner
MIRM Mirum Pharmaceuticals, Inc. Jun 6, 2022 6 -$962K 4 Jun 8, 2022 * Possible Member of 10% Group, 10%+ Owner
LRMR Larimar Therapeutics, Inc. May 10, 2022 1 $0 4 May 11, 2022 Director, * Director by Deputization, 10%+ Owner
PEPG PepGen Inc. May 10, 2022 6 $5M 4 May 10, 2022 Possible Member of 10% Group, 10%+ Owner
PEPG PepGen Inc. May 5, 2022 0 $0 3 May 5, 2022 *Possible Member of 10% Group, 10%+ Owner
TOIIW Oncology Institute, Inc. Nov 12, 2021 11 $100M 4 Nov 16, 2021 Possible Members of 10% Group, 10%+ Owner
XLO Xilio Therapeutics, Inc. Oct 26, 2021 6 $12.4M 4 Oct 28, 2021 Possible Member of 10% Group, 10%+ Owner
XLO Xilio Therapeutics, Inc. Oct 21, 2021 0 $0 3 Oct 21, 2021 *Possible Member of 10% Group, 10%+ Owner
NUVL Nuvalent, Inc. Aug 2, 2021 14 $10.2M 4 Aug 4, 2021 Director, Director by Deputization, 10%+ Owner
NUVL Nuvalent, Inc. Jul 28, 2021 2 $0 4 Jul 30, 2021 Director, Director by Deputization, 10%+ Owner
NUVL Nuvalent, Inc. Jul 28, 2021 0 $0 3 Jul 28, 2021 Director, Director by Deputization, 10%+ Owner
AFIB Acutus Medical, Inc. Jul 19, 2021 2 $15M 4 Jul 21, 2021 Director, Director by Deputization, 10%+ Owner
MIRM Mirum Pharmaceuticals, Inc. Jul 9, 2021 1 -$1.57M 4 Jul 13, 2021 * Possible Member of 10% Group, 10%+ Owner
MIRM Mirum Pharmaceuticals, Inc. Jul 2, 2021 3 -$1.09M 4 Jul 7, 2021 * Possible Member of 10% Group, 10%+ Owner
LRMR Larimar Therapeutics, Inc. Jun 30, 2021 3 $6M 4 Jul 2, 2021 Director, * Director by Deputization, 10%+ Owner
AFIB Acutus Medical, Inc. Jun 17, 2021 2 $0 4 Sep 2, 2021 Director, Director by Deputization, 10%+ Owner
CMAX Deerfield Healthcare Technology Acquisitions Corp. Jun 8, 2021 8 $100M 4 Jun 10, 2021 Director, Director by Deputization, 10%+ Owner
OMIC Singular Genomics Systems, Inc. Jun 1, 2021 8 $33.3M 4 Jun 3, 2021 *Possible Member of 10% Group, 10%+ Owner
OMIC Singular Genomics Systems, Inc. May 26, 2021 0 $0 3 May 26, 2021 *Possible Member of 10% Group, 10%+ Owner
LRMR Larimar Therapeutics, Inc. May 12, 2021 1 $0 4 May 17, 2021 Director, * Director by Deputization, 10%+ Owner